Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005764 · ClinicalTrials.gov registry record · Phase 4
A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
A Phase 4 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00005764 is a Phase 4 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 100 participants.
The verdict
NCT00005764, a Phase 4 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the findings of increased lactic acid and abnormal fat distribution get better when d4T is replaced with abacavir, abacavir plus lamivudine, or Combivir (a pill containing lamivudine plus zidovudine) in HIV-positive patients taking anti-HIV therapy including stavudine (d4T).
Interventions
- DRUG Lamivudine
- DRUG Lamivudine/Zidovudine
- DRUG Abacavir sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2000-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005764
The ClinicalTrials.gov registry entry for NCT00005764 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lamivudine is the first listed.
NCT00005764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005764 about?
NCT00005764 is a clinical study titled "A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients". The purpose of this study is to see if the findings of increased lactic acid and abnormal fat distribution get better when d4T is replaced with abacavir, abacavir plus lamivudine, or Combivir (a pill containing lamivudine plus zidovudine) in HIV-positive patients taking anti-HIV therapy including st...
What is the current status of trial NCT00005764?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2000-05.
What interventions are being tested in trial NCT00005764?
The interventions under investigation include: Lamivudine (DRUG), Lamivudine/Zidovudine (DRUG), Abacavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00005764?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.